Metastatic pancreatic cancer with activating BRAF V600E mutations: A case report

Figure 1 Positron emission tomography/computed tomography of whole body and abdomen before treatment. A: Coronal bitmap of positron emission tomography/computed tomography (PET/CT) fusion image revealed high tumor burden with malignant lesions involving pancreas, liver, multiple bones, and multiple lymph nodes (bilateral neck, clavicle, mediastinum, bilateral hilum of lung, abdomen, pelvis and retroperitoneum; B: CT images revealed multiple low-density lesions in the liver; C: Cross-sectional PET/CT fusion image revealed multiple lesions with elevated ¹⁸F-fluorodeoxyglucose metabolism in liver and lumbar vertebra; D: PET image revealed multiple lesions with elevated ¹⁸F-fluorodeoxyglucose metabolism in liver and lumbar vertebra; E: Maximum intensity projection image revealed high tumor burden with malignant lesions involving pancreas, liver, multiple bones, and multiple lymph nodes (bilateral neck, clavicle, mediastinum, bilateral hilum of lung, abdomen, pelvis and retroperitoneum.

Figure 2 Magnetic resonance imaging of multiple intracranial metastases after first-line chemotherapy. A: Magnetic resonance imaging (MRI) T1-weighted image revealed multiple lesions in the frontal and parietal regions; B: MRI T1-weighted image revealed multiple lesions in the basal ganglia; C: MRI T1-weighted image revealed multiple lesions in the temporal lobe and brainstem; D: MRI T1-weighted image revealed multiple lesions in the brainstem and cerebellum.

Figure 3 Magnetic resonance imaging and computed tomography of abdomen after treatment with first-line chemotherapy. A: Magnetic resonance imaging T2-weighted image revealed multiple lesions in the liver; B: Computed tomography image revealed multiple low-density lesions in the liver.